---
figid: PMC5687693__oncotarget-08-89326-g001
figtitle: Management of intracranial melanomas in the era of precision medicine
organisms:
- NA
pmcid: PMC5687693
filename: oncotarget-08-89326-g001.jpg
figlink: /pmc/articles/PMC5687693/figure/F1/
number: F1
caption: BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib,
  selumitinib, and binimetinib) target the MAP kinase pathway to check tumor growth.
papertitle: Management of intracranial melanomas in the era of precision medicine.
reftext: Grace J. Young, et al. Oncotarget. 2017 Oct 24;8(51):89326-89347.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9633765
figid_alias: PMC5687693__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC5687693__F1
ndex: 3cdeaaa0-ded4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5687693__oncotarget-08-89326-g001.html
  '@type': Dataset
  description: BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib,
    selumitinib, and binimetinib) target the MAP kinase pathway to check tumor growth.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Sos
  - drk
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - rl
  - binimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
